Literature DB >> 9371714

Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.

E Huston1, S Lumb, A Russell, C Catterall, A H Ross, M R Steele, G B Bolger, M J Perry, R J Owens, M D Houslay.   

Abstract

5'-Rapid amplification of cDNA ends, done on poly(A)+ RNA from human U87 cells, was used to identify 420 bp of novel 5' sequence of a PDE4B cAMP-specific phosphodiesterase (PDE). This identified an open reading frame encoding a putative 721-residue 'long-form' PDE4B splice variant, which we term HSPDE4B3. HSPDE4B3 differs from the two known PDE4B forms by virtue of its unique 79-residue N-terminal region, compared with the unique N-terminal regions of 94 and 39 residues found in HSPDE4B1 and HSPDE4B2 respectively. In transfected COS7 cells the two long forms, HSPDE4B1 and HSPDE4B3, had molecular masses of approx. 104 and approx. 103 kDa respectively. Expressed in COS-7 cells, the three HSPDE4B isoforms were found in the high-speed supernatant (cytosol) fraction as well as both the high-speed pellet (P2) and low-speed pellet (P1) fractions. All isoforms showed similar Km values for cAMP hydrolysis (1.5-2.6 microM). The maximal activities of the soluble cytosolic activity of the two long forms were very similar, whereas that of the short form, HSPDE4B2, was approx. 4-fold higher. Particulate-associated HSPDE4B1 and HSPDE4B2 were less active (approx. 40%) than their cytosol forms, whereas particulate HSPDE4B3 was similar in activity to its cytosolic form. Particulate and cytosolic forms of HSPDE4B1 and HSPDE4B3 were similarly inhibited by rolipram {4-[3-(cyclopentoxyl)-4-methoxyphenyl]-2-pyrrolidone}, the selective inhibitor of PDE4 (IC50 0.05-0.1 microM), whereas particulate-associated HSPDE4B2 was profoundly (approx. 10-fold) more sensitive (IC50 0.02 microM) to rolipram inhibition than its cytosolic form (IC50 0.2 microM). The various particulate-associated HSPDE4B isoforms showed very different susceptibilities to solubilization with the detergent Triton X-100 and high NaCl concentration. A novel cDNA, called pRPDE74, was obtained by screening a rat olfactory lobe cDNA library. This contained an open reading frame encoding a 721-residue protein that showed approx. 96% amino acid identity with HSPDE4B3 and is proposed to reflect the rat homologue of this human enzyme and is thus called RNPDE4B3. Alternative splicing of mRNA generated from both the human and rat PDE4B genes produces long and short splice variants that have unique N-terminal splice regions. It is suggested that these alternatively spliced regions determine changes in the maximal catalytic activity of the isoforms, their susceptibility to inhibition by rolipram and mode of interaction with particulate fractions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371714      PMCID: PMC1218954          DOI: 10.1042/bj3280549

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  51 in total

1.  Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IVA1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase.

Authors:  G Scotland; M D Houslay
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

Review 2.  Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes.

Authors:  G B Bolger
Journal:  Cell Signal       Date:  1994-11       Impact factor: 4.315

3.  Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C).

Authors:  P Engels; M Sullivan; T Müller; H Lübbert
Journal:  FEBS Lett       Date:  1995-01-30       Impact factor: 4.124

4.  Chromosomal localization of the human and rat genes (PDE4D and PDE4B) encoding the cAMP-specific phosphodiesterases 3 and 4.

Authors:  C Szpirer; J Szpirer; M Rivière; J Swinnen; E Vicini; M Conti
Journal:  Cytogenet Cell Genet       Date:  1995

5.  Multiple cyclic nucleotide phosphodiesterases.

Authors:  J A Beavo; M Conti; R J Heaslip
Journal:  Mol Pharmacol       Date:  1994-09       Impact factor: 4.436

6.  Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phosphodiesterase (PDE IVD).

Authors:  P A Baecker; R Obernolte; C Bach; C Yee; E R Shelton
Journal:  Gene       Date:  1994-01-28       Impact factor: 3.688

7.  Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum.

Authors:  Y Shakur; M Wilson; L Pooley; M Lobban; S L Griffiths; A M Campbell; J Beattie; C Daly; M D Houslay
Journal:  Biochem J       Date:  1995-03-15       Impact factor: 3.857

8.  Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions.

Authors:  M Lobban; Y Shakur; J Beattie; M D Houslay
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

9.  Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases.

Authors:  G B Bolger; L Rodgers; M Riggs
Journal:  Gene       Date:  1994-11-18       Impact factor: 3.688

10.  The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation.

Authors:  C Sette; S Iona; M Conti
Journal:  J Biol Chem       Date:  1994-03-25       Impact factor: 5.157

View more
  27 in total

1.  Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.

Authors:  Seiko Susuki-Miyata; Masanori Miyata; Byung-Cheol Lee; Haidong Xu; Hirofumi Kai; Chen Yan; Jian-Dong Li
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

2.  Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington's disease.

Authors:  Motomasa Tanaka; Koko Ishizuka; Yoko Nekooki-Machida; Ryo Endo; Noriko Takashima; Hideyuki Sasaki; Yusuke Komi; Amy Gathercole; Elaine Huston; Kazuhiro Ishii; Kelvin Kai-Wan Hui; Masaru Kurosawa; Sun-Hong Kim; Nobuyuki Nukina; Eiki Takimoto; Miles D Houslay; Akira Sawa
Journal:  J Clin Invest       Date:  2017-03-06       Impact factor: 14.808

3.  Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes.

Authors:  S J MacKenzie; S J Yarwood; A H Peden; G B Bolger; R G Vernon; M D Houslay
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

4.  Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior.

Authors:  Rolf T Hansen; Marco Conti; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

5.  Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.

Authors:  S J MacKenzie; M D Houslay
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

6.  Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling.

Authors:  Yun-Feng Li; Yu-Fang Cheng; Ying Huang; Marco Conti; Steven P Wilson; James M O'Donnell; Han-Ting Zhang
Journal:  J Neurosci       Date:  2011-01-05       Impact factor: 6.167

7.  Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors:  P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

8.  Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.

Authors:  M Takahashi; R Terwilliger; C Lane; P S Mezes; M Conti; R S Duman
Journal:  J Neurosci       Date:  1999-01-15       Impact factor: 6.167

Review 9.  PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

Authors:  Miles D Houslay; David R Adams
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

10.  Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform.

Authors:  Malcolm Shepherd; Theresa McSorley; Aileen E Olsen; Lee Ann Johnston; Neil C Thomson; George S Baillie; Miles D Houslay; Graeme B Bolger
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.